by Andrew Blake | Jan 16, 2022
Recently, the U.S. Department of Health and Human Services decided to publish “Practice and Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder” to expand access to medication-assisted treatments (MAT) by exempting...
by The Coleman Institute | Jan 15, 2022
An estimated 2 million people in the United States have a substance use disorder related to opioid pain medications. To put that into perspective, that is 1 in every 13 individuals. Too often these people suffering from addiction feel as if there is no way out. What...
by The Coleman Institute | Jan 14, 2022
What is dopamine? Dopamine is known as a pleasure molecule that is released in the nucleus accumbens area of the brain when we do pleasurable things — like eat food, have sex, or even take prescription opioids (drugs). When dopamine releases in the brain, we...
by The Coleman Institute | Jan 8, 2022
A recent publication by Health and Human Services (HSS) reports that opioid prescriptions in the US peaked at 255 million in 2012 and decreased to 191 million in 2017. Prescribers—and the rest of the world—have become well aware of the unanticipated consequences of...
by The Coleman Institute | Jan 7, 2022
Ramon decided to stop taking methadone during the COVID-19 pandemic. Was it essential or was it elective? Perhaps in Ramon’s case, it was a bit of both. Going to a methadone clinic was never what he pictured for himself. Ramon’s story includes neck and back surgery,...